Skip to content
- Previously CEO of BioMarin, Chiasma (that developed oral octreotide), Bioblast, and Applied Microbiology
- Previously Chairman of Aummune, BioMarin, Bioblast, Chiasma, Omrix, Zymenex, & Peptimmune
- Served the boards of Enobia Pharma and Pharmasset
- Led drug development efforts that resulted in six drug approvals, including Chiasma’a oral octreotide; board member of other companies that received two additional approvals
- Earlier experience: CFO of Regeneron, the founder of the strategy consulting firm RxFDP, and VP of Pfizer Pharmaceuticals
- Co-inventor of 18 issued US patents
- BA from Dartmouth College, and an MBA from the Wharton School, University of Pennsylvania
- Previously Member of the Board of Chiasma (developed oral octreotide) 2007 to 2021
- 15 years MPM Capital
- Lead Partner UBS Oncology Impact Fund
- Founder TriNetX, Acylin, Rekindle, Solasia
- MD Harvard Medical School, PhD MIT Systems Neuroscience, Massachusetts General Internal Medicine Residency
- Former CEO of Bayer Pharmaceuticals Corp. and Region Head, North America
- Previously CEO of four biotech/pharma firms (Cytosolix, Bioblast Pharma, Optherion, Bayer Pharmaceuticals Corp.), Chairman of 2 (Cytosolix, and Ivenix), and Board Member of 6 (Cytosolix, Ascendia Pharmaceuticals, OncoSynergy, Bioblast Pharma, Ivenix, and Optherion)
- Earlier experience: Region Head, UK/Ireland at Bayer, and Vice President of Marketing & Sales at Bayer in USA and Canada
- BSc from University of Toronto, MBA from Ivy School of Business, Western University, and Canadian Securities Course
- More than 40 years of experience in providing strategic advice and reasoned solutions to executives in pharma/biotech, medical technology and diagnostics; specialties include valuation services, business and commercial strategy, business development, competitive intelligence, opportunity assessment
- Held senior positions at Navigant Consulting, Easton Associates, IBM Consulting and The Wilkerson Group; served as Senior Equities Analyst in Biotechnology at Kidder Peabody, Lehman Brothers and Hancock Financial
- Instrumental in launching the M.S. Program in Biotechnology Management and Entrepreneurship at The Katz Program of Yeshiva University.
- BA from Yeshiva University, MA from Columbia University, and MBA from Cornell
